A major transaction has emerged on the Ghana Alternative Exchange (GAX) following the disclosure that Zagadat Capital GH. Ltd has acquired a substantial stake in Intravenous Infusions PLC, signaling growing investor confidence in Ghana’s healthcare and pharmaceutical manufacturing sector.

According to a market notice released through the Ghana Stock Exchange on May 22, 2026, Zagadat Capital acquired 47,514,775 shares in Intravenous Infusions PLC, representing a 17.31% stake in the company.

The acquisition was executed through open-market purchases on the Ghana Alternative Exchange (GAX), with Laurus Africa Securities acting as the executing broker. The transaction was completed on May 18, 2026.

Intravenous Infusions PLC currently has a total issued share capital of 274,410,000 shares, making this one of the most notable substantial shareholding disclosures on the Ghana Alternative Exchange in recent months.

In its statement, Zagadat Capital described the acquisition as a “strategic long-term investment initiative” aimed at supporting Ghana’s healthcare and pharmaceutical manufacturing industry. The investment firm emphasized its confidence in the future growth prospects of Intravenous Infusions PLC and the broader healthcare ecosystem in Ghana.

Importantly, the company clarified that the investment is not intended to trigger a takeover or change control of Intravenous Infusions PLC. Instead, Zagadat Capital stated that the purpose of the investment is to establish a strategic position that supports the company’s long-term growth, sustainability, and value creation for shareholders and stakeholders.

The announcement reflects increasing institutional interest in healthcare-related companies listed on the Ghanaian capital market, especially firms involved in local pharmaceutical production. With governments and investors across Africa placing renewed emphasis on healthcare infrastructure, medicine production, and import substitution, companies such as Intravenous Infusions PLC are becoming strategically important within the economy.

The disclosure was formally issued through the Ghana Stock Exchange under Press Release No. 241/2026 and circulated to market participants, custodians, regulators, registrars, and the investing public.

Market observers are likely to view the transaction as a strong vote of confidence in Intravenous Infusions PLC’s long-term outlook and the future of Ghana’s domestic pharmaceutical manufacturing industry.